-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Molecular Partners AG (NASDAQ:MOLN) Short Interest Down 9.4% in August
Molecular Partners AG (NASDAQ:MOLN) Short Interest Down 9.4% in August
Molecular Partners AG (NASDAQ:MOLN – Get Rating) was the recipient of a large decline in short interest in August. As of August 31st, there was short interest totalling 26,900 shares, a decline of 9.4% from the August 15th total of 29,700 shares. Based on an average daily volume of 13,200 shares, the short-interest ratio is currently 2.0 days.
Molecular Partners Stock Performance
MOLN opened at $6.21 on Wednesday. Molecular Partners has a one year low of $5.50 and a one year high of $32.04. The company has a fifty day moving average price of $6.33 and a 200-day moving average price of $10.36.
Get Molecular Partners alerts:Molecular Partners (NASDAQ:MOLN – Get Rating) last announced its earnings results on Thursday, August 25th. The company reported ($0.15) earnings per share (EPS) for the quarter. The business had revenue of $12.19 million for the quarter. On average, equities research analysts anticipate that Molecular Partners will post 3.79 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several research analysts recently weighed in on the stock. Royal Bank of Canada cut shares of Molecular Partners from an "outperform" rating to a "sector perform" rating in a report on Tuesday, August 30th. SVB Leerink downgraded Molecular Partners from an "outperform" rating to a "market perform" rating and decreased their price target for the company from $30.00 to $8.00 in a research report on Monday, August 29th. Finally, Credit Suisse Group raised Molecular Partners from an "underperform" rating to a "neutral" rating in a research report on Wednesday, May 25th.Institutional Investors Weigh In On Molecular Partners
An institutional investor recently raised its position in Molecular Partners stock. Federated Hermes Inc. boosted its stake in Molecular Partners AG (NASDAQ:MOLN – Get Rating) by 94.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 457,037 shares of the company's stock after purchasing an additional 221,743 shares during the period. Federated Hermes Inc. owned about 1.41% of Molecular Partners worth $9,264,000 at the end of the most recent reporting period. 2.70% of the stock is currently owned by institutional investors and hedge funds.
Molecular Partners Company Profile
(Get Rating)
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus.
Featured Stories
- Get a free copy of the StockNews.com research report on Molecular Partners (MOLN)
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- Is Ford Rolling To A Rebound After Its Q3 Warning
- If You're Hungry for Value, Take a Bite on Ruth's Hospitality Grp
- Has AMD stock stock fallen too far?
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.
Molecular Partners AG (NASDAQ:MOLN – Get Rating) was the recipient of a large decline in short interest in August. As of August 31st, there was short interest totalling 26,900 shares, a decline of 9.4% from the August 15th total of 29,700 shares. Based on an average daily volume of 13,200 shares, the short-interest ratio is currently 2.0 days.
分子合伙公司(纳斯达克:Moln-Get Rating)是空头股数8月份股价大幅下跌的接受者。截至8月31日,空头股数共有26,900股,较8月15日的29,700股下跌9.4%。以日均成交量13,200股计算,目前短息比率为2.0天。
Molecular Partners Stock Performance
分子合作伙伴股票表现
MOLN opened at $6.21 on Wednesday. Molecular Partners has a one year low of $5.50 and a one year high of $32.04. The company has a fifty day moving average price of $6.33 and a 200-day moving average price of $10.36.
Moln周三开盘报6.21美元。分子合伙公司的一年低点为5.50美元,一年高位为32.04美元。该公司的50日移动均线价格为6.33美元,200日移动均线价格为10.36美元。
Molecular Partners (NASDAQ:MOLN – Get Rating) last announced its earnings results on Thursday, August 25th. The company reported ($0.15) earnings per share (EPS) for the quarter. The business had revenue of $12.19 million for the quarter. On average, equities research analysts anticipate that Molecular Partners will post 3.79 EPS for the current fiscal year.
分子合伙公司(纳斯达克:Moln-Get Rating)最近一次公布财报是在8月25日(星期四)。该公司公布了该季度每股收益(EPS)(0.15美元)。该业务本季度的收入为1219万美元。平均而言,股票研究分析师预计分子合伙公司本财年的每股收益将达到3.79股。
Wall Street Analyst Weigh In
华尔街分析师也加入进来
Institutional Investors Weigh In On Molecular Partners
机构投资者看好分子合伙人
An institutional investor recently raised its position in Molecular Partners stock. Federated Hermes Inc. boosted its stake in Molecular Partners AG (NASDAQ:MOLN – Get Rating) by 94.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 457,037 shares of the company's stock after purchasing an additional 221,743 shares during the period. Federated Hermes Inc. owned about 1.41% of Molecular Partners worth $9,264,000 at the end of the most recent reporting period. 2.70% of the stock is currently owned by institutional investors and hedge funds.
一家机构投资者最近提高了对分子合伙公司股票的头寸。联合爱马仕公司最近提交给美国证券交易委员会(美国证券交易委员会)的文件显示,今年第一季度,该公司增持分子合伙公司股份94.2%。在此期间,该公司额外购买了221,743股,持有该公司457,037股股票。在最近一次报告期结束时,联合爱马仕公司拥有分子伙伴公司约1.41%的股份,价值9,264,000美元。2.70%的股票目前由机构投资者和对冲基金持有。
Molecular Partners Company Profile
分子合作伙伴公司简介
(Get Rating)
(获取评级)
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus.
分子伙伴公司是一家临床阶段的生物制药公司,专注于治疗性蛋白质的发现、开发和商业化。它的候选产品包括用于治疗新血管湿性老年性黄斑变性和糖尿病黄斑水肿的候选DARPin药物Abempar,该药物处于第三阶段临床试验;以及针对SARS-CoV-2病毒的多特异性DARPin候选药物MP0420。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Molecular Partners (MOLN)
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- Is Ford Rolling To A Rebound After Its Q3 Warning
- If You're Hungry for Value, Take a Bite on Ruth's Hospitality Grp
- Has AMD stock stock fallen too far?
- 免费获取StockNews.com关于分子伙伴的研究报告(Moln)
- 3家航空公司股票陷入持有格局
- Roku股票下跌,但并未出局
- 福特在第三季度发出警告后是否正在反弹
- 如果你渴望价值,那就尝尝露丝的好客之道吧
- AMD股票是不是跌得太厉害了?
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.
每日收到分子合作伙伴的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯,接收分子合作伙伴和相关公司的最新新闻和分析师评级的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧